Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

David Moreno to Animals

This is a "connection" page, showing publications David Moreno has written about Animals.

 
Connection Strength
 
 
 
0.078
 
  1. Rodríguez-Lobato LG, Cardús O, Mañé-Pujol J, Battram AM, Vaqué-Salsench S, Carpio J, Pérez-Amill L, Calderón H, Martín-Antonio B, Oliver-Caldés A, Lozano E, Moreno DF, Ortiz-Maldonado V, Salas MQ, de Daniel A, Tovar N, Cibeira MT, Rosiñol L, Bladé J, Juan M, Urbano-Ispizua Á, Engel P, Fernández de Larrea C. Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited. Cancer Immunol Res. 2025 Sep 02; 13(9):1374-1390.
    View in: PubMed
    Score: 0.012
  2. Oliver-Caldes A, Mañe Pujol J, Battram AM, Perez-Amill L, Bachiller M, Calderon H, Castella M, Carpio J, Salsench SV, Tovar N, Cardus O, Urbano-Ispizua A, Moreno DF, Rodríguez-Lobato LG, Lozano E, Rosiñol L, Juan M, Martín-Antonio B, Fernández de Larrea C. TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model. Oncoimmunology. 2025 Dec; 14(1):2529632.
    View in: PubMed
    Score: 0.012
  3. Forouzanfar F, Moreno DF, Plassard D, Furst A, Oliveira KA, Reina-San-Martin B, Tora L, Molina N, Mendoza M. Gene-specific transcript buffering revealed by perturbation of coactivator complexes. Sci Adv. 2025 Mar 21; 11(12):eadr1492.
    View in: PubMed
    Score: 0.012
  4. Battram AM, Mañé-Pujol J, Moreno DF, Oliver-Caldés A, Carpio J, Cardus O, Rodríguez-Lobato LG, Urbano-Ispizua Á, Fernández de Larrea C. Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells. Blood Adv. 2025 Feb 11; 9(3):627-641.
    View in: PubMed
    Score: 0.012
  5. Ren L, Moreno D, Baer BR, Barbour P, Bettendorf T, Bouhana K, Brown K, Brown SA, Fell JB, Hartley DP, Hicken EJ, Laird ER, Lee P, McCown J, Otten JN, Prigaro B, Wallace R, Kahn D. Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. J Med Chem. 2024 08 08; 67(15):13019-13032.
    View in: PubMed
    Score: 0.011
  6. Lozano-Ruiz B, Tzoumpa A, Martínez-Cardona C, Moreno D, Aransay AM, Cortazar AR, Picó J, Peiró G, Lozano J, Zapater P, Francés R, González-Navajas JM. Absent in Melanoma 2 (AIM2) Regulates the Stability of Regulatory T Cells. Int J Mol Sci. 2022 Feb 17; 23(4).
    View in: PubMed
    Score: 0.010
  7. Ren L, Grina J, Moreno D, Blake JF, Gaudino JJ, Garrey R, Metcalf AT, Burkard M, Martinson M, Rasor K, Chen H, Dean B, Gould SE, Pacheco P, Shahidi-Latham S, Yin J, West K, Wang W, Moffat JG, Schwarz JB. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2. J Med Chem. 2015 Feb 26; 58(4):1976-91.
    View in: PubMed
    Score: 0.006
  8. Rico E, Alzate JF, Arias AA, Moreno D, Clos J, Gago F, Moreno I, Domínguez M, Jiménez-Ruiz A. Leishmania infantum expresses a mitochondrial nuclease homologous to EndoG that migrates to the nucleus in response to an apoptotic stimulus. Mol Biochem Parasitol. 2009 Jan; 163(1):28-38.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)